KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.

Michael Wang, David Salek, David Belada, Yuqin Song, Wojciech Jurczak, Brad S Kahl, Jonas Paludo, Michael P Chu, Iryna Kryachok, Laura Fogliatto, Chan Y Cheah, Marta Morawska, Juan-Manuel Sancho, Yufu Li, Caterina Patti, Cecily Forsyth, Jingyang Zhang, Robin Lesley, Safaa Ramadan, Simon Rule, Martin Dreyling, ECHO investigators, ECHO Investigators

J Clin Oncol 43(20) 2276-2284

PMID40311141
PMCIDPMC12225732
DOI10.1200/JCO-25-00690
发表日期2025-05-01
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图。
摘要

摘要

PURPOSE: The combination of the Bruton tyrosine kinase inhibitor ibrutinib with bendamustine-rituximab for first-line treatment of mantle cell lymphoma (MCL) prolonged progression-free survival (PFS), but without improvement in overall survival (OS), likely because of toxicity. Acalabrutinib was shown to be efficacious and less toxic than ibrutinib in a head-to-head trial in chronic lymphocytic leukemia and therefore might lead to better outcomes in MCL. METHODS: Patients 65 years and older with previously untreated MCL received acalabrutinib (100 mg twice daily) or placebo (until disease progression or unacceptable toxicity), plus six cycles of bendamustine (90 mg/m2 once daily; days 1 and 2) and rituximab (375 mg/m2 as a single dose; day 1) followed by rituximab maintenance in responding patients for 2 years. Crossover to acalabrutinib at disease progression was permitted. The primary end point was PFS per the independent review committee; overall response rate and OS were secondary end points. RESULTS: In total, 598 patients were randomly assigned, with 299 in each arm. At a median follow-up of 49.8 months using the reverse Kaplan-Meier method, the median PFS was 66.4 months in the acalabrutinib arm and 49.6 months in the placebo arm (hazard ratio [HR], 0.73 [95% CI, 0.57 to 0.94]; P = .0160). Benefit was seen across all subgroups, including those with high-risk features. Overall response/complete response rates were 91.0%/66.6% and 88.0%/53.5% in the acalabrutinib and placebo arms, respectively. OS was not significantly different (HR, 0.86 [95% CI, 0.65 to 1.13]; P = .27). Grade 3 or greater adverse events were reported in 88.9% and 88.2% in the acalabrutinib and placebo arms, respectively. CONCLUSION: The combination of acalabrutinib with bendamustine-rituximab significantly improved PFS. Clinical benefit of acalabrutinib with bendamustine-rituximab was achieved with manageable toxicity.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.CONSORT diagram showing patient disposition. BR, bendamustine-rituximab.
非 KM Figure
FIG 2.PFS and OS with and without COVID-19 deaths and PFS by acalabrutinib exposure. (A) PFS in the full analysis population. (B) PFS when COVID-19 deaths were censored. (C) OS in the full analysis population, including crossover. (D) OS when COVID-19 deaths were censored. Symbols in all panels indicate censored data. BR, bendamustine-rituximab; HR, hazard ratio; NE, not estimable; OS, overall survival; PD, progressive disease; PFS, progression-free survival.
非 KM Figure
FIG 3.Subgroup analysis of PFS (full analysis population). Forest plot of subgroup analysis for PFS assessed by the independent review committee. a Per interactive voice/web response system record. BR, bendamustine-rituximab; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; MCL, mantle cell lymphoma; MIPI, Mantle Cell Lymphoma International Prognostic Index; PFS, progression-free survival.
非 KM Figure